Meeting Materials NOW Available! – Miltefosine Capsules

Posted by on October 16, 2013

October 18, 2013 8:00 a.m. to 5:00 p.m.: Meeting of the Anti-Infective Drugs Advisory Committee 

At this meeting, the committee will discuss the safety and effectiveness of new drug application (NDA) 204684, miltefosine capsules, submitted by Paladin Therapeutics, Inc., for the proposed indication of treatment of patients with visceral (involving internal organs), mucosal (involving areas such as inside the mouth and nose), and cutaneous (involving the skin) leishmaniasis, an infection caused by a parasite.

Please click HERE to access the FDA meeting materials associated with this meeting. In the meeting materials, you will find the original meeting announcement, the agenda, committee roster(s), webcast information, FDA proposed questions and other relevant briefing information.

Please click HERE to view this meeting’s original announcement.

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact

Interested in learning about ISS’ expert approach to Advisory Committee Meetings? Click below in order to find out for yourself!  

Generic Blog CTA for Ad Comm Approach